Preclinical studies demonstrate that ATG inhibits proliferation, migration, invasion, and EMT in BC cells, principally by downregulating eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) (Luo et al., 2021). This evidence concerns the gene EIF4EBP1 and breast cancer.